This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 May 19;379(9829):1858-9.

doi: 10.1016/S0140-6736(12)60610-2.

Extending the reach of BRAF-targeted cancer therapy

Geoffrey T Gibney¹, Vernon K Sondak

Affiliations

PMID: 22608322
DOI: 10.1016/S0140-6736(12)60610-2

Comment

Extending the reach of BRAF-targeted cancer therapy

Geoffrey T Gibney et al. Lancet. 2012.

. 2012 May 19;379(9829):1858-9.

doi: 10.1016/S0140-6736(12)60610-2.

Authors

Geoffrey T Gibney¹, Vernon K Sondak

Affiliation

¹ Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

PMID: 22608322
DOI: 10.1016/S0140-6736(12)60610-2

No abstract available

PubMed Disclaimer

Comment on

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Falchook GS, et al. Lancet. 2012 May 19;379(9829):1893-901. doi: 10.1016/S0140-6736(12)60398-5. Lancet. 2012. PMID: 22608338 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program